Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9823132.7Aexternal-prioritypatent/GB9823132D0/en
Priority claimed from GBGB9823192.1Aexternal-prioritypatent/GB9823192D0/en
Priority claimed from GBGB9825117.6Aexternal-prioritypatent/GB9825117D0/en
Priority claimed from GBGB9826392.4Aexternal-prioritypatent/GB9826392D0/en
Application filed by Pfizer Res & DevfiledCriticalPfizer Res & Dev
Publication of AR019492A1publicationCriticalpatent/AR019492A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
La invencion proporciona formulaciones farmacéuticas de liberacion controlada para administracion oral que contienen un inhibidor GMPc PDE-5. Lasformulaciones son utiles, entre otros, en el tratamiento o prevencion de la disfuncion sexual.The invention provides controlled release pharmaceutical formulations for oral administration containing a cGMP PDE-5 inhibitor. The formulations are useful, among others, in the treatment or prevention of sexual dysfunction.
ARP9901053281998-10-231999-10-21
PHARMACEUTICAL COMPOSITIONS OF CONTROLLED LIBERATION
AR019492A1
(en)
ADAMANTAN DERIVATIVES, PROCEDURES FOR THE PREPARATION, PHARMACEUTICAL COMPOSITION, PROCEDURE FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITION, AND THE USE OF SUCH DERIVATIVES FOR THE MANUFACTURE OF MEDICINES
PHARMACEUTICAL FORMULATION THAT INCLUDES BIFOSPHONATES, PROCESS FOR PREPARATION, USE OF THE FORMULATION FOR THE MANUFACTURE OF A MEDICINAL PRODUCT, PARALA METHOD INHIBITION OF OSEA REABSORTION, AND METHOD FOR THE TREATMENT AND PREVENTION OF OSTEOPOROSIS